| [March 23, 2017] |
 |
Millendo Therapeutics Announces Data Presentations for MLE4901 and ATR-101 at ENDO 2017 and Kisspeptin 2017
Millendo
Therapeutics, Inc., a clinical-stage biopharmaceutical company
focused on developing novel treatments for endocrine diseases caused by
hormone dysregulation, today announced that data from its MLE4901 and
ATR-101 programs will be presented in multiple poster and oral
presentations at The Endocrine Society's (ENDO) 99th Annual
Meeting and Expo, being held April 1-4 at the Orange (News - Alert) County Convention
and Exhibition Center in Orlando, Florida, and at the Kisspeptin 3rd
World Conference, an ENDO satellite meeting, on March 30-31 at the Rosen
Centre Hotel in Orlando, Florida.
|
|
|
Details of the MLE4901 program presentations are as follows:
|
|
|
|
Title: Neurokinin 3 Receptor Antagonism as a Novel
Treatment for Menopausal Hot Flushes: A Phase 2, Randomised,
Double-Blind, Placebo-Controlled Trial
|
|
|
|
Meeting: Kisspeptin 2017: Brain & Beyond
|
|
Poster: 57
|
|
Date/ Time: Thursday, March 30, 2017, 9:00 - 11:00 AM EDT
|
|
Location: Rosen Centre Hotel
|
|
|
|
Meeting: ENDO 2017
|
|
Oral Session: Late Breaking Developments in Female
Reproduction and Menopause Treatment
|
|
Date/Time: Monday, April 3, 2017, 12:30 - 12:45 PM EDT
|
|
Room: W414A, Orange County Convention and Exhibition Center
|
|
|
|
Title: Neurokinin B and kisspeptin regulation of
gonadotropin secretion and hot flushes in postmenopausal women
|
|
|
|
Meeting: Kisspeptin 2017: Brain & Beyond
|
|
Poster: 71
|
|
Date/Time: Thursday, March 30, 2017, 9:00 - 11:00 AM EDT
|
|
Location: Rosen Centre Hotel
|
|
|
|
Title: Trial in Progress: A Double-Blind, Randomized,
Parallel-Group, Placebo-Controlled Phase 2b Study of MLE4901, a
Novel NK3 Receptor Antagonist, for the Treatment of PCOS
|
|
|
|
Meeting: ENDO 2017
|
|
Poster: SAT 099
|
|
Date/Time: Saturday, April 1, 2017, 1:00 - 3:00 PM EDT
|
|
Room: Expo Hall, Orange County Convention and Exhibition
Center
|
|
|
|
Title: Disconnect in PCOS: Symptoms Leading to Diagnosis
Vs. Most Bothersome Symptoms
|
|
|
|
Meeting: ENDO 2017
|
|
Poster: SAT 101
|
|
Date/Time: Saturday, April 1, 2017, 1:00 - 3:00 PM EDT
|
|
Room: Expo Hall, Orange County Convention and Exhibition
Center
|
|
|
|
Title: MLE4901, a Neurokinin 3 Receptor Antagonist, Acts
Upstream of Pituitary GnRH to Reduce Testosterone Secretion in
Male Dogs
|
|
|
|
Meeting: Kisspeptin 2017: Brain & Beyond
|
|
Poster: 64
|
|
Date/Time: Friday, March 31, 2017, 9:00 - 11:00 AM EDT
|
|
Location: Rosen Centre Hotel
|
|
|
|
Meeting: ENDO 2017
|
|
Poster: SUN 485
|
|
Date/Time: Sunday, April 2, 2017, 1:00 - 3:00 PM EDT
|
|
Room: Expo Hall, Orange County Convention and Exhibition
Center
|
|
|
|
Details of the ATR-101 program presentations are as follows:
|
|
|
|
Title: Trial in Progress: A Phase 2 Randomized,
Double-Blind, Placebo-Controlled Study of ATR-101 for the
Treatment of Cushing's Syndrome
|
|
|
|
Meeting: ENDO 2017
|
|
Poster: SAT 410
|
|
Date/Time: Saturday, April 1, 2017, 1:00 - 3:00 PM EDT
|
|
Room: Expo Hall, Orange County Convention and Exhibition
Center
|
|
|
|
Title: ATR-101 and ER Stress-Inducing Chemotherapeutic
Agents Synergize to Induce Cytotoxicity in Adrenocortical Cancer
Cells
|
|
|
|
Meeting: ENDO 2017
|
|
Poster: MON 396
|
|
Date/Time: Monday, April 3, 2017, 1:00 - 3:00 PM EDT
|
|
Room: Expo Hall, Orange County Convention and Exhibition
Center
|
|
|
About Millendo Therapeutics, Inc.
Millendo Therapeutics is focused on developing novel treatments for
endocrine diseases caused by hormone dysregulation. Our mission is to
build a leading endocrine company that creates distinct and
transformative treatments for a wide range of diseases where there is a
significant unmet medical need. We are advancing two product candidates
in five indications: MLE4901, designed to address Polycystic Ovary
Syndrome (PCOS) and Vasomotor Symptoms (VMS), and ATR-101 for the
treatment of Classic Congenital Adrenal Hyperplasia (CAH), Endogenous
Cushing's Syndrome (CS), and Adrenocortical Carcinoma (ACC). www.millendo.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170323005494/en/
[ Back To TMCnet.com's Homepage ]
|
